What is Lumicell?
Lumicell is a pioneering medical technology company dedicated to transforming the landscape of cancer surgery. Its core innovation, the LUMISIGHT and Lumicell DVS system, utilizes advanced fluorescence imaging to illuminate residual cancer cells in real-time during surgical procedures. This capability allows surgeons to achieve more complete tumor removal, significantly improving surgical outcomes for patients, particularly in breast cancer treatment. By integrating seamlessly into existing operating room workflows, Lumicell provides healthcare professionals with the actionable data necessary to reduce the incidence of repeat surgeries and enhance long-term patient health. The company operates at the intersection of diagnostic imaging and surgical intervention, positioning itself as a critical player in the precision medicine market.
How much funding has Lumicell raised?
Lumicell has raised a total of $42.7M across 7 funding rounds:
Private Equity
$2.7M
Series B
$1M
Private Equity
$1.6M
Series A
$1.6M
Private Equity
$6.8M
Series C
$28.7M
Debt
$350K
Private Equity (2011): $2.7M, investors not publicly disclosed
Series B (2013): $1M, investors not publicly disclosed
Private Equity (2013): $1.6M, investors not publicly disclosed
Series A (2014): $1.6M, investors not publicly disclosed
Private Equity (2016): $6.8M, investors not publicly disclosed
Series C (2017): $28.7M with participation from BlueIO and LaunchCapital
Debt (2020): $350K led by PPP
Key Investors in Lumicell
BlueIO
Blueio is a builder capital platform focused on creating a cleaner, healthier, and safer world through the formation and scaling of innovative solutions.
LaunchCapital
LaunchCapital is a venture capital firm that supports entrepreneurs at the seed and early stages, providing hands-on assistance and growth capital.
PPP
Public-Private Partnership
What's next for Lumicell?
With the recent strategic investment, Lumicell is entering a critical phase of market expansion and operational scaling. The company is expected to focus on the widespread adoption of its LumiSystem across major oncology centers, leveraging its recent regulatory successes to capture significant market share. Future strategic initiatives will likely involve expanding the clinical applications of its imaging technology to other solid tumor types, thereby broadening its addressable market. As the firm transitions from a development-focused entity to a commercial-stage leader, the focus will remain on maintaining high clinical standards while optimizing the supply chain for its diagnostic products. This growth phase is supported by a strong foundation of institutional backing, ensuring that Lumicell remains at the forefront of surgical innovation and patient-centric care.
See full Lumicell company page
